/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...
/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...
Stocks that traded heavily or had substantial price changes on Wednesday: MillerKnoll, Peloton rise; Progress Software, NextEra Energy fall
What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.23%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq ($IUXX ) (QQQ ) is up +0.26%. Stocks are mixed, with the S&P 500 earlier...
Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.32%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.33%. Stock index futures this morning are mildly lower, following losses...
The trio all have late-stage therapies with blockbuster potential.
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.